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Background: Painful diabetic neuropathy (PDN) is a serious, polymorphic, and 
prevalent complication of diabetes mellitus. Most PDN treatment guidelines recommend 
a selection of drugs based on patient comorbidities. Despite the large numbers of med-
ications available, most randomized clinical trials (RCTs) conducted so far have yielded 
unsatisfactory outcomes. Therefore, treatment may require a personalized approach 
based on pain phenotype or comorbidities.
Methods: To evaluate whether or not a patient’s pain phenotype or comorbidities can 
influence the response to a specific PDN treatment, we conducted a systematic review 
using two different approaches: pain phenotype and associated comorbidities-based 
treatment.
results: Out of 45 identified papers, 7 were thoroughly reviewed. We found four RCTs 
stratified according to pain phenotype with three main results: (1) paroxysmal pain had 
a better response to pregabalin; (2) the preservation of thermal sensation or nociception 
anticipated a positive response to the topical treatment of pain; and, (3) after a failure to 
duloxetine (60 mg/day), the patients with evoked pain or severe deep pain had a better 
response to association of duloxetine/pregabalin while those with paresthesia/dyses-
thesia benefited from duloxetine monotherapy (120  mg/day). By contrast, the other 
three papers provided weak and even contradictory evidence about PDN treatment 
based on comorbidities.
conclusion: Although more studies are needed to provide an adequate recommenda-
tion for clinical practice, our systematic review has provided some evidence that PDN 
phenotyping may optimize clinical outcomes and could, in the future, lead to both less 
empirical medicine and more personalized pain therapeutics.
Keywords: comorbidity, chronic neuropathic pain, diabetes mellitus, painful diabetic neuropathy, pain phenotype, 
randomized clinical trial, systematic review
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iNtrODUctiON
Diabetic neuropathy (DN) is the most common complication 
of diabetes mellitus (DM) with a random prevalence ranging 
from 30 to 50% in individuals with this disease, depending on 
the method used for diagnosis (1). In addition, DM is the most 
common cause of polyneuropathy in the western world, as 
approximately 50% of polyneuropathies are caused by DM (2). 
Besides that, DN is one of the most impactful chronic diabetes 
complications, regarding quality of life (QOL), because it is the 
primary cause of lower limb amputations (85%). It is also directly 
related to chronic neuropathic pain and its comorbidities, namely, 
depression, anxiety, and insomnia (1, 2).
Diabetic polyneuropathy is defined as “a symmetrical, distal 
and progressive degeneration of the sensorimotor and autonomic 
peripheral fibers, attributable to metabolic and microvascular 
changes in consequence of chronic hyperglycemia (DM) and other 
cardiovascular risk factors” (1).
Currently, there are about 415 million adults with diabetes in 
the world (3). Among them, 16–26% suffer from chronic pain-
ful diabetic neuropathy (PDN), which means that they present 
symptoms of neuropathic pain continuous or intermittent for 
more than 3 months (2, 4). The pain is typically distal, signifi-
cantly worse at night, and presenting proximal and symmetrical 
progression: discomfort initially predominant in the toes, feet, 
and ankles. Regarding the pain phenotype, patients usually 
describe “burning” associated with a “tingling” sensation, and 
only approximately 15% present allodynia (4–6).
Thus far, PDN diagnosis and treatment remains problematic 
and is still open to debate and questioning. Among all PDN 
patients, unfortunately, up to 39% have never received any treat-
ment for their pain while 12.5% had never even reported their 
symptoms to doctors (4). Moreover, in most recent therapeutic 
clinical trials for PDN, only an average of 47% of patients who 
received duloxetine and pregabalin achieved a 50% reduction in 
pain scales (5). Another multicentric trial, conducted in France 
(6) has presented significant data: only 38% of patients correctly 
diagnosed with PDN were receiving any of the first-line drugs 
that are consensually recommended.
Finally, in the last 7  years, there has been a proliferation of 
algorithms and guidelines for the treatment of PDN (7–12) and, in 
the literature (7), there are at least nine reasons that could explain 
these facts: (1) high prevalence of DN; (2) social and economic 
impact of DN; (3) interdisciplinary nature of the disease; (4) the 
cost of available resources; (5) the lack of reliable information; (6) 
the lack (and necessity) of data on benefit versus risk; (7) there 
are at least 34 different drugs recommended to PDN in literature; 
(8) inconsistent methods to assess the quality of trials; and (9) 
systematic reviews generally do not include unpublished clinical 
studies. It is worth noting that there are some contradictory recom-
mendations, such as the ones issued by the American Academy of 
Neurology (10), the Toronto Consensus (11), and, more recently, 
the American Diabetes Association position statement about DN 
(12), which could have been generating confusion among clinicians.
Therefore, there is a considerable global burden caused by 
PDN and a steady and insoluble demand from both its sympto-
matic and comorbidities treatment.
OBJectives
Our aim was to assess whether pain phenotype or comorbidities 
influence the patient’s response to a specific PDN treatment. Two 
different approaches were utilized to conduct a systematic review, 
one focusing on treatment based on pain phenotype and the other 
on comorbidities.
MetHODs
We included randomized clinical trials (RCTs) of treatments for 
PDN in which participants were stratified by pain phenotype or 
comorbidities in the analysis of therapy efficacy. The literature 
review was conducted on the Medline database via PubMed by 
using the following index terms: “clinical trials and painful dia-
betic neuropathy,” “human diabetic neuropathy and neuropathic 
pain,” “pain phenotype and randomized study and clinical trials” 
and “comorbidity and painful diabetic neuropathy.” We primarily 
analyzed articles from 2010 to 2016 but included articles from 
2009 to 2017 due to high citation index.
We examined titles and abstracts to select the relevant reports. 
Two authors (LR and ES) independently screened the studies that 
were identified by the literature search. We retrieved and exam-
ined the full text of selected studies for compliance with eligibility 
criteria. We collected the outcome variables of the intervention 
effect according to the stratification as the authors presented in 
the article. Two authors (LR and ES) independently assessed each 
included study using the Cochrane Collaboration tool for assess-
ing risk of bias (13).
Definition of treatment Based on Pain 
Phenotype
It is a treatment for PDN in which the selection of therapy is strati-
fied by the pain phenotype, the latter meaning pain characteristics 
regarding signs and symptoms. These features  of individual pati-
ents or subgroups of patients can increase or decrease the response 
to a specific treatment (12, 14). Regardless of etiology, neuropathic 
pain has a strong clinical consistency (14) and can be categorized 
in five dimensions (pain phenotypes): (1) evoked pain (allodynia 
or hyperalgesia); (2) paroxysmal pain (electric shock, sharp); (3) 
deep pain (compression, tightness); (4) superficial pain (burning); 
and (5) paresthesia and dysesthesia (tingling, brushing).
Definition of treatment Based on PDN 
comorbidities
It is a treatment for PDN where the selection of therapy is based 
on concomitant pathologic or disease process. In PDN, there is 
usually the coexistence of at least one or more disease processes, 
for instance, cardiovascular disease, anxiety, depression, obesity, 
autonomic neuropathy, obstructive sleep apnea, peripheral artery 
disease, nephropathy (dialysis), retinopathy, dementia, and non-
alcoholic steatohepatitis.
resULts
Initially, we found 45 articles. We excluded 39 studies because 
they were neither randomized nor original. However, just one 
3Rolim et al. Therapeutics for PDN: A Systematic Review
Frontiers in Neurology | www.frontiersin.org June 2017 | Volume 8 | Article 285
non-randomized study was added because it was a large (2,575 
patients) prospective and provided real world-based analysis. 
Therefore, we identified seven studies that were included in the 
systematic review: four RCTs based on pain phenotype and three 
based on comorbidities (two randomized and one observational 
study).
treatment Based on Pain Phenotype
We identified four studies. In the most recent randomized 
controlled trial (15), the authors found that the combination 
of moderate doses of imipramine (75 mg/daily) and pregabalin 
(300  mg/daily) was more effective in the symptomatic treat-
ment of PDN than the monotherapy of one of these drugs, but 
at the expense of an increased dropout rate, associated with an 
increased severity and frequency of adverse events (AEs). In 
this trial, no impact of pain phenotype was registered in the 
response rates for any of the four groups (imipramine, pregaba-
lin, the combination of both drugs, and the placebo). However, 
patients with paroxysmal pain tended to respond to pregabalin 
more often than those without paroxysmal pain (38 versus 10%, 
respectively, p = 0.05).
Another double-blind (without placebo) group (16) exam-
ined data from the COMBO-DN trial (17) and studied patients 
with PDN who lacked a satisfactory response after 8  weeks 
of monotherapy (duloxetine or pregabalin in doses of 60 and 
300  mg, respectively). The authors of this research sought 
to predict better the analgesic efficacy of different treatment 
regimens based on painful phenotypes to prescribe a more 
stratified and personalized treatment for PDN. Patients in an 
initial duloxetine therapy (60  mg/day) who lacked a satisfac-
tory response particularly benefited from the association of 
pregabalin (300 mg/day) when presented an evoked or intense 
deep pain phenotype, while those patients with a paresthesia 
and dysesthesia phenotype benefited from an increased dose 
of duloxetine (120  mg/day). On the other hand, patients who 
received pregabalin (300 mg/day) for initial therapy without a 
satisfactory response benefited from both duloxetine (60 mg/day) 
association or increased doses of pregabalin (600  mg/day), 
regardless of pain phenotype.
A third controlled and randomized trial (18) stratified by pain 
phenotype was the first to prove that the approach based on pain 
phenotype could result in a better therapeutic effect. The authors 
remarked that patients with an evoked pain could be treated 
with a blocking-sodium-channel agent such as oxcarbazepine. 
However, only 11% (n = 9) of the intention-to-treat population 
(n = 83) of patients had PDN. Nonetheless, in this work, it was the 
preservation of thermal sensation that anticipated the response to 
oxcarbazepine, not the evoked pain.
The fourth double-blind, placebo-controlled trial examined 
the effect of clonidine gel (0.1%) in PDN (19), applied three times 
per day for 12 weeks on both feet and ankles. Although the group 
as a whole presented a trend toward improvement on the pain 
scale (p = 0.07), groups that had previously responded to topical 
capsaicin (0.1%), which means that the patients concerned have 
a functional nociceptor, significantly improved in pain after the 
application of clonidine gel. The treatment was safe and did not 
show any significant AEs.
treatment Based on the comorbidities  
of PDN
We found three studies. The first was a randomized study (20) 
that sought to assess the baseline characteristics of demogra-
phy and comorbidities as predictors of the analgesic effect of 
duloxetine and pregabalin in patients with PDN. The authors 
investigated 804 patients from another trial (the multicenter 
COMBO-DN trial (17)) at baseline and after 8 weeks of mono-
therapy with duloxetine (60 mg/day) or pregabalin (300 mg/day). 
No comorbidities or demographic characteristics at the predic-
tor baseline of the analgesic effect were found during the use 
of the two drugs that were studied. However, both groups of 
patients reacted better to the medications if they did not have a 
mood disorder.
The second study that was identified was a 6-month-long 
prospective, multicenter, observational trial that evaluated 
2,575 patients with PDN in the real world (21). In this study, 
there were no inclusion or exclusion criteria. The purpose of 
this analysis was to evaluate the impact of comorbidities before 
initiating pain therapy in the analgesic efficacy and on different 
pain scales [brief pain inventory (BPI)] (17) of two drug groups: 
AD (antidepressant: duloxetine) and AC (anticonvulsant: 
gabapentin, pregabalin). The authors found that 90% of patients 
had comorbidities: 70% presented hypertension, 37% presented 
macroangiopathy, 42% presented other chronic pain—especially 
joint pain or “backache,” and 25% presented depression. 
Furthermore, patients with depression or with other chronic pain 
had an analgesic response (BPI) that was greater with duloxetine 
(60 mg/day) than with AC, although the dosage of gabapentin 
and pregabalin did not reach the levels that were considered to be 
effective. The authors concluded that multiple comorbidities are 
the rule in patients with PDN living in the community and the 
choice of first-line drugs according to the comorbidity of PDN 
may be rational.
The third study (22) that we reviewed was a randomized, 
placebo-controlled trial that examined three first-line drugs 
(amitriptyline, duloxetine, and pregabalin) for PDN regard-
ing analgesic efficacy, impact on QOL, on polysomnography 
(PS), and on performance to carry out sensorimotor activities 
(PSMA). This study presented no statistically significant differ-
ence in pain relief during the use of drugs, but there were notable 
differences in terms of impact on the PS and PSMA. Pregabalin 
increased sleep time and concomitantly decreased the number 
of nighttime awakenings and periodic leg movements (PLMs). 
However, duloxetine and amitriptyline decreased sleep time REM 
and increased PLMs. On the other hand, pregabalin increased 
the non-REM phase and only duloxetine significantly increased 
PSMA.
A summary of findings and their evidence is illustrated in 
Table  1 with all of the studies that we have reviewed regard-
ing the treatment of PDN stratified by pain phenotype and by 
comorbidities.
As can be seen in Table  2, the studies were generally clas-
sified as moderate to high quality. The most biased risks that 
were verified were the lack of reporting of the randomiza-
tion and allocation process and the losses in the follow-up 
period.
tABLe 1 | Summary of findings: the evidence for PDN treatment, based on pain phenotype and comorbidity.
type of study N treatment results: phenotype–comorbidity conclusion and evidence reference
Randomized, multicenter, double-
blind, and placebo-controlled
73 4 groups: placebo, pregabalin, imipramine, 
and combination of both
No impact of pain phenotype on rate  
response among groups
The percentage of patients with paroxysmal  
pain tended to respond more often to pregabalin  




multinational, and stratified by pain 
phenotype data from COMBO-DN 
study
339 2 groups (after 8 weeks of duloxetine or 
pregabalin and without satisfactory response): 
high dose (duloxetine 120 or pregabalin 600) 
versus a combination of both (duloxetine 
60 + pregabalin 300)
Patients who received duloxetine (60 mg) as  
initial therapy had: (1) better response to the  
association of duloxetine + pregabalin with  
evoked or severe tightness and (2) greater benefit  
from a high dose of duloxetine (120 mg) with  
paresthesia–dysesthesia phenotype. In patients  
with severe pain, there was a tendency to respond  
better to high-dose monotherapy than association
Patients who received pregabalin (300 mg)  
as initial therapy benefited from both  
duloxetine association (60 mg) and a  
high dose of pregabalin (600 mg),  
independent of pain phenotype
(16)
Randomized, double-blind, placebo-
controlled, and phenotype-stratified 
study
83 2 groups: placebo and oxcarbazepine The number of patients needed to treat to obtain  
one patient with more than 50% of pain relief was  
6.9 in the total sample, 3.9 in the evoked pain  
phenotype, and 13 in the non-irritable nociceptor  
phenotype. However, it was the preservation of  
thermal sensation that anticipated oxcarbazepine  
response
Oxcarbazepine was more efficacious for reliefs of  
PDN in patients with the irritable versus  
the non-irritable phenotype. However, in this  
study, the etiology of neuropathy was  
heterogeneous: from the total of intention-to– 
treat (ITT) patient population (n = 83), only  
11% had PDN (n = 9). Therefore, the  





182 2 groups: placebo and topical clonidine In individuals who felt any level of pain to capsaicin,  
clonidine was superior to a placebo (p < 0.05). In  
patients with a capsaicin pain rating >2 (0–10), the  
mean decrease in foot pain was 2.6 for active  
compared to 1.4 for a placebo (p = 0.01)
Topical clonidine gel significantly reduces the  
level of foot pain in PDN subjects with  
functional nociceptors. Screening for  
cutaneous nociceptor function may help  
to distinguish candidates for topical therapy in PDN
(19)
Randomized, double-blind, 
multinational, data from COMBO-DN 
study
804 2 groups (duloxetine and pregabalin) to 
investigate baseline demographics and 
comorbidities as predictors of the analgesic 
effect on PDN
It did not reveal any specific demographic or  
disease characteristic predictor of  
analgesia in PDN treatment
Duloxetine and pregabalin were more  
beneficial for patients without any mood disorder
(20)
Prospective, observational 
(6 months), multicentric, and real-
world study
2,575 2 groups: antidepressive (AD) (duloxetine) and 
anticonvulsive (AC) (gabapentin, pregabalin)
Better treatment responses with AD versus  
AC were observed in patients with depression  
or joint pain. However, the dosage of AC  
did not reach the effective level
The choice of first-line drugs according to  
the comorbidity of PDN could be rational.  
However, it was an observational and non- 
randomized study
(21)
Randomized, placebo-controlled 83 4 groups: placebo, amitriptyline, duloxetine, 
and pregabalin
No difference between groups in terms of analgesic  
efficacy
All three treatments were relatively well tolerated,  
but there was no impact on QOL
Pregabalin increased sleep time and  
decreased the PLM, whereas duloxetine  
and amitriptyline decreased sleep time  
REM and increased PLM. However, it was a  
short (28-day) dosing study
(22)
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tABLe 2 | Risk of bias and quality of the RCT included in the systematic review.













(15) Low risk Low risk Low risk Low risk Uncleara Low risk High
(16) Low risk Low risk Low risk Low risk High risk Low risk Moderate
(17) Low risk Low risk Low risk Low risk Uncleara Low risk High
(18) Low risk Low risk Low risk Low risk Uncleara Low risk High
(19) Unclear Unclear Low risk Low risk Low risk Low risk Moderate
(20) Unclear Unclear Low risk Low risk Low risk Low risk Moderate
aLosses in the follow-up, ITT analysis.
RCT, randomized clinical trial.
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DiscUssiON
Currently, consensus guidelines for symptomatic PDN treatment, 
while still rather empirical, recommend a stepwise approach: drugs 
from first, second, and third lines (1, 7, 12). Since PDN presents 
with a high rate of associated comorbidities, as we have shown 
in this systematic review, several authors recommend that the 
choice of drugs should be guided by comorbidities. Patients with 
depression, for instance, could initially receive an antidepressant 
(AD), while patients with anxiety could preferably receive an anti-
convulsant (AC) (1, 7–9). Notwithstanding, such conduct remains 
based mainly on common sense and physicians’ expertise rather 
than scientific evidence. As listed in Table 1, for the same drug 
(duloxetine), there is strong evidence that it can be more beneficial 
in patients without mood disorder and weak evidence to the con-
trary; in other words, it could be more efficacious in patients with 
depression. Nevertheless, in clinical practice, the choice and rec-
ommendation of drugs based on comorbidities are understandable 
and even prudent because the principle of personalized medical 
treatment is always desirable. Additionally, multiple comorbidities 
are the rule and not the exception in patients with PDN (21).
Moreover, although a therapeutic approach of neuropathic 
pain based on pain phenotype has been considered rational, 
reasonable, and recommended in the last two decades by experts 
(5, 23), scientific evidence for this proposition in patients with 
PDN is recent and not yet consensual since guidelines have not 
yet endorsed this concept. In fact, we have found only four RCTs 
stratified by the pain phenotype and with three main results: (1) 
paroxysmal pain had a better response to pregabalin; (2) the pres-
ervation of thermal sensation or nociception anticipated a positive 
response to the topical treatment of pain; and (3) after 8 weeks 
of duloxetine (60 mg/day) as an initial therapy and a failure to 
respond to the pain score (BPI) of at least 30%, the patients with 
evoked pain or severe deep pain phenotype had a better response 
to association of duloxetine +  pregabalin (60 +  300  mg daily, 
respectively), while those with the paresthesia and dysesthesia 
phenotype showed greater benefit from a high dose of duloxetine 
in monotherapy (120 mg/day).
On the other hand, in real-world medicine, two phenomena 
have caught the attention of different researchers who study 
neuropathic pain in general and PDN in particular.
First, despite the current advent of new drugs for neuropathic 
pain and the frequent use of “rational polypharmacy,” a combined 
treatment, the results of different clinical trials considering pain 
relief remain rather limited as only 47% of patients in duloxetine 
and pregabalin trials have achieved a 50% pain reduction (23). 
Despite there are many possible reasons for these modest results, 
the lack of an initial approach based on pain phenotype in most 
clinical trials (22) could be a plausible explanation. Recent evidence 
has shown that treatment based on pain phenotype is advanta-
geous and seems to be promising for PDN (Table 1). However, in 
clinical practice, this paradigm shift is more challenging to imple-
ment than it initially appears to be, especially for those unskilled 
or clinical practitioners, since stratification by pain phenotype 
requires specific training on how to obtain accurate data from the 
medical history and careful clinical examination (13, 23).
Second, one of the main reasons and criteria for treating 
patients with neuropathic pain is the intensity of pain. In fact, we 
know that the worse the pain is, the worse the QOL is; further, the 
cost of living increases (24). However, this approach has recently 
been questioned by some researchers (25) who argue that the 
biggest problem in some trial is that chronic pain is not a simple 
concept and there is no single and comprehensive approach to 
assessing the suffering of an individual with pain. They speculate 
that treatments based on a visual analog scale (0–10) misrepresent 
the clinical care and have brought about adverse consequences 
to individuals and general society. These authors propose that 
multiple measures are needed to assess an individual patient, 
his/her particular pain, and its causes and consequences (25). 
Nonetheless, there is some evidence that in patients with PDN and 
severe pain (16), high-dose monotherapy of pregabalin (600 mg/
day) or duloxetine (120 mg/day) seems to be more beneficial than 
the combination of both in moderate dose (300 + 60 mg/day).
There are some weaknesses in this systematic review. First, 
the number of included studies was small (seven studies in total) 
despite the extensive literature search. Second, notwithstanding 
the fact that the studies which were included presented moderate 
to high quality (Table 2), they were too heterogeneous to provide 
an adequate evidence base for clinical practice recommendations. 
Third, some studies included analyses that were prespecified ver-
sus those that were secondary or post hoc and were not corrected 
for multiplicity.
In summary, currently the number and quality of available 
studies are insufficient to recommend which pain phenotype 
could have the best response to the individualized PDN treat-
ment. However, evidence is beginning to suggest that the 
phenotyping of pain may optimize clinical outcomes and could 
lead to both less empirical medicine and more personalized pain 
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therapeutics. In conclusion, there is a present need to maximize 
the efficaciousness of the available neuropathic pain medications. 
Therefore, future randomized studies should have a larger num-
ber of patients, stratified by pain phenotype and screened for the 
nociceptor function in the skin.
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